Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10201/27588

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorZimmermann, U.es
dc.contributor.authorWoenckhaus, C.es
dc.contributor.authorTeller, S.-
dc.contributor.authorVenz, S.-
dc.contributor.authorLangheinrich, M.-
dc.contributor.authorProtzel, C.-
dc.contributor.authorMaile, S.-
dc.contributor.authorJunker, H.-
dc.contributor.authorGiebel, J.-
dc.date.accessioned2012-05-21T12:09:36Z-
dc.date.available2012-05-21T12:09:36Z-
dc.date.issued2007-
dc.identifier.issn0213-3911es
dc.identifier.urihttp://hdl.handle.net/10201/27588-
dc.description.abstractThere is increasing evidence that Annexin AI (ANX AI) expression is dysregulated in several carcinomas and tumour cell lines. In order to gain insight into the putative role of ANX AI in tumorigenesis, clinical outcome and metastatic potential of conventional renal cell carcinomas (CRCCs) we investigated the expression of ANX AI in CRCCs and metastases. Furthermore, it was elucidated whether ANX AI overexpression affects migratory potential in Caki-1 cells. ANX AI immunohistochemistry was performed on 33 samples of CRCCs and 10 metastases. ANX AI expression was assessed in 12 samples by 2-dimensional gelelectrophoresis (2-DE), subsequent mass spectrometry and RT-PCR. Immunohistochemical data were statistically correlated with pathological parameters, amount of eosinophilic cells and clinical outcome. Furthermore, a haptotactic migration assay was done on Caki-1 cells transfected with ANX AI. Immunostaining for ANX AI was found in 18 tumours and all metastases investigated. Intensity of immunohistochemical staining correlated to Fuhrman grade, amount of eosinophilic cells and clinical outcome. 2-DE and RT-PCR confirmed the presence of ANX AI in neoplastic tissue. Overexpression of ANX AI did not significantly influence cell migration. From these findings ANX AI expression seems to be related to Fuhrman grade, clinical outcome and metastatic potential of CRCCs. Thus ANX AI could serve as a prognostic marker for tumour progression.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.languageenges
dc.publisherMurcia : F. Hernándezes
dc.relation.ispartofHistology and histopathologyes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectKidneyes
dc.subjectCanceres
dc.subject.other616.6 - Patología del sistema genitourinarioes
dc.titleExpression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcomees
dc.typeinfo:eu-repo/semantics/articlees
Aparece en las colecciones:Vol.22, nº 5 (2007)



Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.